van Vollenhoven RF - Search Results

1

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J; Swefot study group. van Vollenhoven RF, et al. Lancet. 2012 May 5;379(9827):1712-20. doi: 10.1016/S0140-6736(12)60027-0. Epub 2012 Mar 29. Lancet. 2012. PMID: 22464340 Clinical Trial.

2

[Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].

Larsson P, Bratt J, Harju A, van Vollenhoven R, Klareskog L. Larsson P, et al. Lakartidningen. 2001 Feb 21;98(8):828-31. Lakartidningen. 2001. PMID: 11265568 Review. Swedish.

3

Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.

van Vollenhoven RF, Klareskog L. van Vollenhoven RF, et al. Arthritis Rheum. 2003 Jun;48(6):1500-3. doi: 10.1002/art.11027. Arthritis Rheum. 2003. PMID: 12794816 Free article.

4

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

van Vollenhoven R, Harju A, Brannemark S, Klareskog L. van Vollenhoven R, et al. Ann Rheum Dis. 2003 Dec;62(12):1195-8. doi: 10.1136/ard.2003.009589. Ann Rheum Dis. 2003. PMID: 14644858 Free PMC article.

5

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious.

van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. van Vollenhoven RF, et al. Arthritis Res Ther. 2003;5(6):R347-51. doi: 10.1186/ar1005. Epub 2003 Oct 1. Arthritis Res Ther. 2003. PMID: 14680509 Free PMC article.

6

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF. Jonsdottir T, et al. Among authors: van vollenhoven rf, van vollenhoven a. Ann Rheum Dis. 2004 Sep;63(9):1075-8. doi: 10.1136/ard.2003.018093. Epub 2004 Apr 5. Ann Rheum Dis. 2004. PMID: 15066863 Free PMC article.

7

Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis.

Wick MC, Lindblad S, Weiss RJ, Klareskog L, van Vollenhoven RF. Wick MC, et al. Among authors: van vollenhoven rf. Ann Rheum Dis. 2005 Jan;64(1):134-7. doi: 10.1136/ard.2004.020636. Epub 2004 Apr 19. Ann Rheum Dis. 2005. PMID: 15096329 Free PMC article.

8

Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description.

Wick MC, Lindblad S, Klareskog L, Van Vollenhoven RF. Wick MC, et al. Among authors: van vollenhoven rf. Ann Rheum Dis. 2004 Jul;63(7):848-52. doi: 10.1136/ard.2003.015172. Ann Rheum Dis. 2004. PMID: 15194582 Free PMC article.

9

Switching between biological agents.

van Vollenhoven RF. van Vollenhoven RF. Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S115-21. Clin Exp Rheumatol. 2004. PMID: 15552524 Review.

10

Benefits and risks of biological agents: lymphomas.

van Vollenhoven RF. van Vollenhoven RF. Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S122-5. Clin Exp Rheumatol. 2004. PMID: 15552525 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

486 results

Search Page